“Drug Delivery Technologies market set to grow to $355bn by 2024” says new Visiongain report

28 February 2019
Pharma

Visiongain has published a new pharma report Drug Delivery Technologies Market Forecast 2019-2029: Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular, Nasal/Buccal Drug Delivery Technologies, Biologics, Vaccines.

The Drug Delivery Technologies Market is estimated to grow at a CAGR of 7.8% from 2019 to 2029, driven by exciting new technologies and the potential of extending product life by developing new formulations.

Over the last ten years, the global drug delivery technologies market has witnessed a significant increase in the number of drug delivery companies offering innovative technologies to pharmaceutical manufacturers. Drug delivery technology is an important enabling technology for pharmaceutical products. These platforms are often used by pharmaceutical companies for various reasons, which importantly include the extension of product lifecycle.

There are companies developing new technologies to take advantage of the potential for growth that is abundant in this market. This rapidly expanding market provides growth opportunities for developers willing to invest in R&D. This report profiled the selected companies: 3M, Alkermes PLC, Altea Therapeutics Corporation, Antares Pharma Inc., Applied Pharma Research S.A. (APR), Becton, Dickinson & Company and others.

The lead analyst commented that "The potential use of drug delivery technologies in product lifecycle management and the enhancement of drug efficacy in many therapeutic sectors will act as drivers for growth of the market over the coming decade. This is mainly due to the rising demand from pharmaceutical companies looking to innovate and improve the marketability of their drugs. The potential of extending the patent life of a drug by developing new formulations will act as a driver for the market as it will prompt pharma companies to seek to maximise the return on investment from each marketed drug."

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

“Global Urology Devices market set to grow to $9.3bn by 2023” says new Visiongain report

The market is driven by a number of factors such as aging population, technological advancements, and increasing awareness programs.

21 May 2019

Read

“In Vitro Diagnostics (IVD) market set to grow to $91bn by 2024” says new Visiongain report

In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.

14 May 2019

Read

“Indian Pharmaceutical market set to grow to $71bn by 2024” says new Visiongain report

Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.

09 May 2019

Read

“Global mRNA Vaccines and Therapeutics market set to grow to $5.5bn by 2024” says new Visiongain

The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.

07 May 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever
WOOCS 2.2.1